Acute and Chronic Phases of Complex Regional Pain Syndrome in Mice are Accompanied by Distinct Transcriptional Changes in the Spinal Cord by Joseph J Gallagher et al.
MOLECULAR PAIN
Gallagher et al. Molecular Pain 2013, 9:40
http://www.molecularpain.com/content/9/1/40RESEARCH Open AccessAcute and chronic phases of complex regional
pain syndrome in mice are accompanied by
distinct transcriptional changes in the spinal cord
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Background: CRPS is a painful, debilitating, and often-chronic condition characterized by various sensory, motor,
and vascular disturbances. Despite many years of study, current treatments are limited by our understanding of the
underlying mechanisms. Little is known on the molecular level concerning changes in gene expression supporting
the nociceptive sensitization commonly observed in CRPS limbs, or how those changes might evolve over time.
Results: We used a well-characterized mouse tibial fracture/cast immobilization model of CRPS to study molecular,
vascular and nociceptive changes. We observed that the acute (3 weeks after fracture) and chronic (7 weeks after
fracture) phases of CRPS-like changes in our model were accompanied by unique alterations in spinal gene
expression corresponding to distinct canonical pathways. For the acute phase, top regulated pathways were:
chemokine signaling, glycogen degradation, and cAMP-mediated signaling; while for the chronic phase, the
associated pathways were: coagulation system, granzyme A signaling, and aryl hydrocarbon receptor signaling. We
then focused on the role of CcL2, a chemokine that we showed to be upregulated at the mRNA and protein levels
in spinal cord tissue in our model. We confirmed its association with the nociceptive sensitization displayed in this
model by demonstrating that the spinal but not peripheral administration of a CCR2 antagonist (RS504393) in CRPS
animals could decrease mechanical allodynia. The spinal administration of CcL2 itself resulted in mechanical
allodynia in control mice.
Conclusions: Our data provide a global look at the transcriptional changes in the spinal cord that accompany the
acute and chronic phases of CRPS as modeled in mice. Furthermore, it follows up on one of the top-regulated
genes coding for CcL2 and validates its role in regulating nociception in the fracture/cast model of CRPS.
Keywords: Complex regional pain syndrome, CcL2, Chemokine, Chronic pain, Spinal cord, Microarray analysis,
Transcriptome, Pathway analysisBackground
Complex regional pain syndrome (CRPS) is a painful,
debilitating, and often-chronic condition with an esti-
mated incidence rate of 26.2 per 100,000 person years
[1]. While acute CRPS sometimes improves with early
and aggressive physical therapy, CRPS present for a
period of one year or more seldom spontaneously* Correspondence: djclark@stanford.edu
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reproduction in any medium, provided the orresolves. The syndrome encompasses a disparate collec-
tion of signs and symptoms involving the sensory, motor
and autonomic nervous systems, cognitive deficits, bone
demineralization, skin growth changes and vascular
dysfunction [2]. Current therapies for CRPS including
physical, interventional, pharmacological, rehabilitative
and alternative are limited in their effectiveness, and
none are routinely curative of the chronic condition
[3,4]. The acute phase of the condition is often charac-
terized by edema and warmth, and is thought to be
supported by neurogenic inflammation [5-7]. Alterations
in CNS structure and function may be more importantral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chronic phase of the CRPS [8].
The molecular analysis of peripheral mechanisms
supporting CRPS has been extensive. Human studies
have focused on dysfunctional signaling through auto-
nomic and peptidergic neurons [9-11]. Other work has
shown abnormal levels of cytokines in the skin of CRPS
limbs [12]. More recently changes in the adaptive system
of immunity have been demonstrated [13]. To better
understand these changes, a tibial fracture/cast immo-
bilization model of CRPS has been developed in rodents
displaying nociceptive sensitization, bone demineraliz-
ation, edema and warmth [14,15]. This model also reca-
pitulates the human observations of abnormal peripheral
neural signaling and cytokine generation, particularly in
the first several days after removal of cast immo-
bilization. The fracture/cast model has not to this point
been utilized for the purpose of understanding the more
chronic features of CRPS, though nociceptive changes
are persistent for months in these animals.
The development of pain involves a complicated
sequence of events ranging from changes in neuronal
properties [16] to alterations in gene transcription and
protein levels [17,18]. While many successes have been
achieved through the selection of individual molecules
for study as they participate in pain, a complementary
approach has been to study changes in the expression
levels of large numbers of genes in hypothesis-free fash-
ion using expression arrays and similar molecular tools.
A recent meta-analysis of pain related gene expression
studies on spinal cord and dorsal root ganglion tissue
revealed both similarities and differences across a range
of pain models [19]. These authors discovered that
two genes, Reg3b (regenerating islet-derived 3 beta;
pancreatitis-associated protein) and CcL2 (chemokine
[C-C motif] ligand 2), were up-regulated in almost every
dataset, included in their analysis, suggesting possible
core roles in supporting persistent pain.
To this point no array-based studies have been pro-
vided using a model of CRPS, a condition which has
features separate from most acute, inflammatory and
neuropathic etiologies of pain [10]. Furthermore, the
striking transition of CRPS from an acute to a more
chronic state suggests that analyses need to be conduc-
ted at more than one timepoint. Very few array-based
analyses have commented on changes in gene expression
over time. We hypothesized that array-based spinal cord
gene expression studies using the fracture-cast model of
CRPS would reveal timepoint-dependent genes and
pathways relatively unique to the CRPS model, that a set
of core genes might be shared with other models of per-
sistent pain, and that at least one significantly changed
gene could be shown to be functionally related to noci-
ceptive sensitization in this model.Results
CRPS mice exhibit transient increases in temperature and
edema in addition to long-lasting nociceptive
sensitization in the injured limb
Ipsilateral and contralateral measurements of hindpaw
temperature and edema, two commonly observed symp-
toms in CRPS patients, were performed at 3, 5 and
7 weeks post-fracture. Both temperature and edema
demonstrated similar profiles, exhibiting transients in-
creases identified at the 3-week, but not the 5- or 7-
week timepoints. An increased temperature in the
contralateral hindpaw, as compared to baseline, was ob-
served at the 3-week timepoint only (Figure 1A,B).
Mechanical hypersensitivity, assessed using Von Frey
filaments, identified a significant and persistent reduc-
tion – up to 7 weeks post-fracture - in the injured
hindpaw compared to measurements of the contralateral
hindpaw or control mice. Inspection of the mechanical
hypersensitivity of the contralateral hindpaw suggested a
modest decrease that did not reach significance at the 3
and 5 weeks (Figure 1C). Reduced weight bearing was
present in the injured hindpaw and persisted at both
timepoints assessed, extending from 3 to 7 weeks after
fracture (Figure 1D).
Microarray expression analysis from ipsilateral spinal cord
identifies distinct profiles at 3 and 7 weeks post-fracture.
We identified the genes significantly regulated at the 3-
and 7-week timepoint, with respect to the control group
(absolute fold change > 1.5, adjusted p-value < 0.05). 199
genes were identified as significantly regulated at the 3-
week timepoint with 98 of these genes also identified as
significantly regulated at the 7-week timepoint. 62 genes
were unique to the 7-week timepoint. Half of the 122
genes with increased expression at the 3 week timepoint
maintained increased expression at the 7-week timepoint
(61 genes), while 38 of the 97 genes with decreased ex-
pression at the 3-week timepoint maintained decreased
expression at the 7-week timepoint with the remaining
genes showing no differential expression at the 7-week
timepoint. No genes were identified as reversing their
expression from over expressed to under expressed or
vice versa between timepoints.154 genes are significantly
regulated at the 7-week timepoint with 103 genes
increased and 51 genes decreased (Additional file 1:
Table S1; Additional file 2: Table S2).
CRPS results in altered transcriptional programs in the
spinal cord
Ingenuity Pathway Analysis (IPA) identified specific net-
works that were dysregulated in the spinal cord 3 and
7 weeks following fracture. Canonical pathways with a
cutoff p-value < 0.05 were considered statistically signifi-
cant. Canonical pathways, indicating wide changes in
Figure 2 Canonical pathway analysis. CRPS affects transcriptional programs unique to each of the acute and chronic timepoints. All pathways
were scored and ranked according to Ingenuity Pathway Analysis using Fisher’s exact test. The dotted line indicates the threshold value of p<0.05.
Figure 1 Physiological and behavioral changes in CRPS mice. CRPS mice display increased temperature (A) and edema (B) on the affected
hindpaw at 3 weeks post-fracture. In addition, they show signs of mechanical allodynia (C) and decreased weight bearing (D) for up to 7 weeks
after fracture. **p<0.01, *** p<0.001. n=8/group. Errors bars=S.E.M.
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Figure 3 Transcriptional pathway analysis and validation of
transcript mRNA expression. IPA identified interacting networks
affecting cell signaling. Up-regulated transcripts are marked with red
(A). SPRR1a, GAL, and PDYN transcripts were validated by quantita-
tive PCR. The dotted line indicates control measures (B). *** p<0.001.
n=4/group. Errors bars=S.E.M.
Figure 4 Increase in spinal CcL2 mRNA and protein levels in
CRPS mice. 3 weeks following fracture, CRPS mice show a
significant increase in spinal CcL2 levels at the mRNA (A) and
protein (B) levels, compared to both control (*) and the 7-week
timepoint (#). *** p<0.001. n=4/group. Errors bars=S.E.M.
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tween the two timepoints. At 3 weeks, the main regu-
lated pathways were chemokine signaling, glycogen
degradation II, cAMP-mediated signaling, glycogen deg-
radation III, role of IL-17A in arthritis, agranulocyte ad-
hesion and diapedesis, IL-22 signaling, agrin interactions
at neuromuscular junction, IL-17A signaling in gastric
cells, and role of JAK family kinases in IL-6-type cyto-
kine signaling. At the 7-week timepoint, the effected
pathways were: coagulation system, granzyme A Signal-
ing, aryl hydrocarbon receptor signaling, acute phase
response signaling, granulocyte adhesion and diapedesis,
agranulocyte adhesion and diapedesis, MSP-RON
signaling pathway, thiosulfate disproportionation III
(Rhodanese), GM-CSF signaling, and agrin interactions
at neuromuscular junction (Figure 2). In addition to
these canonical pathways, we identified the following
top biological functions associated, to different degrees,
with both timepoints: Cellular movement, cancer, car-
diovascular system development and function, organis-
mal development, nutritional disease, cell death and
survival, nucleic acid metabolism, small molecule bio-
chemistry, cell-to-cell signaling and interaction, molecu-
lar transport, hematological system development and
function, immune cell trafficking, inflammatory re-
sponse, tissue development, cellular function and
maintenance, cell-mediated immune response, cellular
development, lipid metabolism, cell morphology, hyper-
sensitivity response (Additional file 3: Table S3).
Furthermore, qPCR measures of transcript expression
allowed us to validate the upregulation of some of the genes
(SPRRA1a, GAL, and PDYN) involved in a cell-to-cell
signaling pathway (Figure 3A,B), a pathway with particular
relevance to nociceptive signaling. Additional validation
transcripts are shown in Additional file 4: Figure S1A,B.
No changes were observed in the expression of astrocyte
and macrophage markers, GFAP and Iba1, respectively
(Additional file 4: Figure S1C).
Spinal CcL2 mRNA and protein levels are increased at 3
but not 7 weeks post-fracture
Both our array data and previous array studies have identi-
fied CcL2 as a possible common chronic pain gene. CcL2
mRNA levels were increased at the 3- but not 7-week
timepoint (Figure 4A). Similarly, CcL2 protein levels were
increased at the 3-week timepoint only (Figure 4B).
Intrathecal, but not intraplantar, administration of a CCR2
antagonist leads to transient reduction in mechanical
hypersensitivity 3 and 7 weeks post-fracture
To assess the role of CcL2 signaling in pain behavior,
we pharmacologically blocked a major CcL2 receptor
(CCR2) at 3 and 7 weeks post-fracture using a CCR2
antagonist, RS504393.
Gallagher et al. Molecular Pain 2013, 9:40 Page 5 of 11
http://www.molecularpain.com/content/9/1/40Intrathecal administration of the CCR2 antagonist at
the high dose (3 μg) led to statistically significant reduc-
tions in mechanical hypersensitivity 1, 3 and 6 hours
after injection 3 weeks post-fracture; statistically signifi-
cant reductions 7 weeks post-fracture were observed 1
and 3 hours after injection but did not reach significance
at the 6 hour timepoint (Figure 5A,C). No differences in
high dose response were observed at 24 hours after in-
jection. The low dose response (0.3 μg) did not display
any statistically significant reduction in mechanical
hypersensitivity at 3 or 7 weeks post-fracture. Similarly,
intraplantar administration of the CCR2 antagonist at
two doses (1 and 10 μg) did not affect mechanical hyper-
sensitivity at 3 or 7 weeks post-fracture (Figure 5B,D).
An additional study testing the effects of a higher CCR2
antagonist dose (30 μg) failed to show anti-nociceptive
efficacy (data not shown).
Both intrathecal and intraplantar CcL2 induce transient
mechanical hypersensitivity
A dose-dependent transient mechanical hypersensitivity
was observed following intrathecal and intraplantar ad-
ministration of CcL2 (Additional file 5: Figure S2A,B);
measurements were taken 1, 3, 6 and 24 hours after in-
jections. Statistical analysis identified a Dose × Time
interaction in both administration routes (Intrathecal,
(A): 2-way ANOVA; Dose × Time Interaction, F-value =Figure 5 Amelioration of mechanical allodynia in CRPS mice following
antagonist, RS504393. Intrathecal RS504393 (3 μg) resulted in increased m
(*) and control mice (#). This was true for both the 3- (A) and 7-week (C) ti
* p<0.05; ** p<0.01.n=8/group. Errors bars=S.E.M.14.30; p < 0.0001. Intraplantar, (B): 2-way ANOVA; Dose ×
Time Interaction, F-value = 7.98; p < 0.0001).
Intrathecal doses of 10 and 100 ng were capable of in-
ducing mechanical hypersensitivity 1 and 3 hours after
injection with the higher dose demonstrating hypersensi-
tivity 6 hours after injection. The higher dose induced
significantly greater hypersensitivity compared to the
lower doses at the 1, 3 and 6-hour timepoint (Additional
file 5: Figure S2A).
Intraplantar administration of CcL2 at increased doses
(100 and 500 μg) demonstrated similar profiles with in-
creased mechanical hypersensitivity at 1, 3 and 6-hour
timepoints for both low and high doses. A dose-
dependent effect was also noted with the higher dose in-
ducing significantly greater hypersensitivity at the 3 and
6-hour timepoints (Additional file 5: Figure S2B).
Discussion
Our lack of effective treatments for CRPS may be the re-
sult, at least in part, of a lack of knowledge of the mole-
cules and mechanisms supporting the disease. Using a
hypothesis-free approach to gene discovery involving
expression arrays constitutes a novel approach to under-
standing this condition. For our studies, we employed a
previously characterized model of CRPS involving limb
fracture and cast immobilization in rodents [20]. Our re-
sults showed that these animals develop behavioral signsintrathecal, but not intraplantar, administration of the CCR2
echanical thresholds in the affected paw compared to vehicle-treated
mepoints. Intraplantar injections failed to show any efficacy (B,D).
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and mechanical allodynia in addition to physiological
signs characteristic of clinical CRPS such as temperature
changes and edema in the affected hindpaw. Further-
more, we demonstrated that the acute (3 weeks) and
chronic (7 weeks) phases of CRPS in our model are ac-
companied by unique changes in spinal gene expression.
A diverse array of biological pathways were suggested to
be activated in the spinal cord tissue of fracture/cast
mice, many of which currently have little appreciated
relevance to pain or the manifestations of CRPS. On the
other hand, one of the genes prominently up-regulated
in the acute phase is CcL2, a gene found previously to
be a possible common pain gene in many array studies
[19]. This up-regulation was confirmed both at the
mRNA and protein levels. Finally, the spinal administra-
tion of a CCR2 antagonist in CRPS animals decreased
mechanical allodynia while both the spinal and periph-
eral administration of CcL2 itself resulted in mechanical
allodynia in control mice. Our results point to a diverse,
changing, and previously unappreciated complexity of
genes possibly involved in the varied manifestations of
CRPS. At the same time, our studies confirm that there
may be at least one gene involved in CRPS that is shared
with chronic neuropathic and inflammatory pain.
Acute vs. Chronic stages of CRPS
Chronic pain is a debilitating condition affecting many
aspects of the patient’s life including reduced quality of
life (>50%), negative impact on relationships (29%), job
loss or reduced job responsibilities (>50%), increased
rates of depression (30%), and twice the likelihood of
suicide while awaiting treatment [21]. Many forms of
chronic pain begin with an acute injury or syndrome.
For CRPS patients, a relatively acute or “warm” syn-
drome characterized by pain, edema and warmth often
gives way to a “cold” phase in which pain persists after
the resolution of the vascular changes [10]. Unfortu-
nately, it is difficult to predict the circumstances under
which acute pain will transition into a chronic state. This
is partly due to our limited understanding concerning
the molecular mechanisms of pain, in general, and to a
lack of a clear evolution point between the acute and
chronic phases, in particular.
Apart from many cases observed in children [22],
CRPS often becomes a chronic clinical problem. It is
possible that segregating the acute effects from the
chronic ones could enable us to target the acute changes
in an effort to prevent the chronification of pain. We
have delineated, for the first time, the spinal transcrip-
tomic changes in acute (3 weeks characterized by
allodynia, unweighting, warmth and ede ma) and
chronic (7 weeks, characterized by allodynia and
unweighting without vascular changes) stages of CRPS-like changes in mice. We identified molecular pathways
unique to each of the acute and chronic phases. Com-
parison analysis of the microarray data obtained at the
two timepoints revealed the top functional pathways in-
volved in the acute phase as: cellular movement, cancer,
cardiovascular system development and function, organ-
ismal development, nutritional disease, and cell death
and survival. These pathways are consistent with the
early stage CRPS pathology in our model. For instance,
bone fracture and acute pain both can have immense
global effects on both sensory and motor function, and
as such, could be associated with a certain level of cellu-
lar re-organization (involvement of functions such as
cellular movement and cell death and survival) at the
spinal level. Similarly, the weight loss associated with the
earlier timepoints in our model could account for the in-
volvement of pathways such as organismal development
and nutritional disease. As for the more chronic phase,
the top pathways were: inflammatory response, hemato-
logical system development and function, immune cell
trafficking, cell-to-cell signaling and interaction, and cel-
lular movement. These pathways parallel the chronic
phase of CRPS in our model, with particular emphasis
on the neuro-immune component (inflammatory re-
sponse and immune-cell trafficking). The chronic pain
phenotype also implies central sensitization and thus ex-
plains the involvement of pathways such as cell-to-cell
signaling and interaction and cellular movement. On the
other hand, pathways such as those involved in cancer
are more difficult to relate to CRPS, a benign condition.
Perhaps the activation of these pathways is best viewed
not as evidence of transformation of cells to a malignant
state, but rather reflective of profound changes in func-
tion. Despite some overlap in the transcriptomic changes
between the two timepoints, significant changes in gene
expression reflected in the changes in pathway analysis
imply a progression or transition in the pathology of the
disease, mirroring the phenotypic changes observed in
our model.
Our findings complement previous microarray studies
undertaken both in dorsal root ganglia (DRG) and spinal
cord samples in different animal models of pain [19].
For instance, acute transcriptomic changes were repor-
ted in the zymosan model of DRG inflammation and
included pathways such as: defense response, immune
response, regulation of body fluid levels, osteoblast pro-
liferation, hemopoietic or lymphoid organ development,
leukocyte proliferation, neuronal generation, epithelial
cell proliferation, etc. 3 days after the induction of in-
flammation [23]. In models of neuropathy, functional
gene clusters relating to complement activation, antigen
processing/presentation, neuronal axonogenesis, cell
adhesion, synaptic transmission, etc. were identified [19].
While it could be argued that the type of injury
Gallagher et al. Molecular Pain 2013, 9:40 Page 7 of 11
http://www.molecularpain.com/content/9/1/40(neuropathic versus inflammatory) could potentially be a
more important contributing factor than the timecourse
[24] of injury/pain, we suggest that both the type of
insult (inflammatory versus neuropathic) and the time-
course are reflected in the transcriptional changes and
may be intertwined. For instance, inflammation and
neuropathy could both be linked to a multifactorial syn-
drome such as CRPS, and the contribution of each could
change with time.
Role of CcL2 in nociceptive processing
Similar to previous findings [25], our data shows that both
the intrathecal and intraplantar administration of CcL2 re-
sult in mechanical allodynia. This is in agreement with the
global role of CcL2 in nociception. The function of CcL2
in peripheral nociception, in particular at the level of the
DRG and afferent neurons, has been well described. Elec-
trophysiological studies have shown that CcL2 depolarizes
DRG neurons in neuropathic animals [26,27] and sensi-
tizes nociceptors through the activation of TRP channels
and the inhibition of K+ conduction [26,28,29]. As elegant
as these studies are, our own data involving the local injec-
tion of a selective CCR2 antagonist suggest that distal
peripheral sites of CcL2 action are not prominent in
supporting sensitization in our model.
In contrast, intrathecal injection of the same CCR2 an-
tagonist reduced mechanical allodynia significantly, thus
demonstrating that the CcL2 upregulation observed in
the array and ELISA experiments was functional in our
model. Unfortunately, CcL2 expression in the spinal
cord remains controversial [30]. Although we did not
specifically explore the question in our model, it has
been shown that injured and uninjured neurons [31-33],
astrocytes [34], and microglia [35] could all be potential
sources for the elevated levels of CcL2. We did deter-
mine, however, that the upregulation of spinal CcL2
expression occurs in the absence of any measurable
transcriptional changes in astrocyte (GFAP) and macro-
phage (Iba1) markers at both the 3- and 7-week time
points. It is possible that CRPS is associated with
microglial activation without wide-spread microglial pro-
liferation, with activated microglia secreting a variety of
pro-inflammatory cytokines and chemokines that are
implicated in nociception. Though it is known that
endogenous CcL2 can induce microglial activation in a
mouse model of neuropathic pain [36], it is not known if
this is true for the CRPS model. It would therefore be
interesting to examine microglial and astrocytic re-
sponses following the fracture/cast procedure, whether
these cells are responsible for some of the gene expres-
sion demonstrated by the arrays, and the responses of
glial cells to the spinal administration of CcL2.
Another notable point is the timecourse of CcL2
upregulation in relation to phenotypic changes in ourmodel. We show a transient upregulation of CcL2
mRNA and protein in the ipsilateral spinal cord at
3 weeks after fracture with the return to levels very close
to control samples by 7 weeks. However, mechanical
allodynia in this model persists well beyond 7 weeks,
and retains its sensitivity to a CCR2 antagonist. One ex-
planation is that CcL2 and other mediators play roles in
the early cascade of events that lead to enhanced noci-
ceptive sensitization that persists even after the reso-
lution of the early changes. Thus at later time points
even normal levels of CcL2 may support allodynia. In
fact, plasma levels of CcL2 in CRPS patients were found
to show no correlation with the duration of the CRPS
[37], and CSF levels of CcL2 and GFAP were found to
be upregulated in only 50% of patients [38], suggesting
that mechanisms other than persistent chemokine acti-
vation are at play.
CcL2/CCR2 As potential therapeutic targets
The involvement of CcL2 in pain makes it an attractive
candidate for therapeutic intervention. Indeed, multiple
studies have shown that antagonizing CCR2, a major re-
ceptor for CcL2, is efficacious in reversing allodynia and
hyperalgesia in animal models of neuropathic pain
[39,40]. As mentioned above, our data show that spinal
but not local hindpaw administration of the CCR2
antagonist, RS504393, attenuates mechanical sensitivity
observed in our CRPS model. These observations are dis-
tinct from a report where CcL2-induced CCR2 receptor
activation was shown to occur mainly in the peripheral
nervous system in a demyelination model of neuropathic
pain [41]. These differences could be due to the possibility
that in our CRPS model, unlike neuropathy models, CcL2
plays its primary role in the CNS. While CcL2 itself is suf-
ficient to induce mechanical sensitivity in the periphery,
this type of signaling may not be necessary to induce and/
or maintain CRPS-related nociception in the effected
hindpaw. This is not to say peripheral inflammatory
mediators are not involved in CRPS. Similar to clinical
observations [42], data from our rat tibia fracture/cast
immobilization model of CRPS has shown the upregu-
lation of many peripheral inflammatory cytokines [43,44],
thus drawing attention to the peripheral mechanisms that
support some chronic pain syndromes.
The CCR2 antagonist AZD2423 was recently evaluated
as an analgesic in a well-designed clinical trial, but had
no efficacy in patients with posttraumatic neuralgia [45].
On the other hand, additional persistent pain states re-
main viable targets for this or similar drugs. Alterna-
tively, it is possible that, in humans, CcL2 does not play
as strong a role or perhaps is only one of many media-
tors ultimately converging on the same pathways to
maintain pain in CRPS. Consistent with this notion, our
array analysis revealed that multiple CC chemokine
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making a reduction in signaling through one molecule
unlikely to completely eliminate the nociceptive sensiti-
zation characterizing this syndrome. Perhaps a more
systems-oriented approach would be useful when
targeting the treatment of complex and multifactorial
pathologies such as chronic pain.
Limitations and future directions
While this work has identified molecules and pathways
hopefully expanding our understanding of acute and
more chronic forms of CRPS, our approach has several
caveats. Microarray probes do have inherent biases in
their design due to their reliance on annotated genes. A
more comprehensive approach, such as RNA sequen-
cing, could provide a truly unbiased view [46]. In
addition, the current manuscript demonstrates a noci-
ceptive role of CcL2 in a mouse model of CRPS but it
does not inform us about its source. Localizing CcL2
and/or CCR2 to a specific cell type would improve our
understanding of the function of CcL2 in CRPS.
Finally, the current work examines spinal effects only
while it is well known that CRPS has significant periph-
eral [44,47] and supraspinal [48,49] correlates. Ultim-
ately, understanding how changes in gene expression
and function at each of these sites contribute will be
necessary to fully understand the syndrome.
Conclusions
We demonstrate broad and distinct changes in gene
expression in the ipsilateral cord during the acute and
chronic phases of “CRPS” in a tibia fracture/immo-
bilization model in mice. These data allow the comparison
on a broad-based molecular level with other models of
chronic pain, and support the generation of novel hypoth-
eses regarding mechanisms supporting acute and more
chronic forms of CRPS. One particular gene of interest,
CcL2, was found to be upregulated in the acute phase of
CRPS and was pharmacologically shown to be associated
with nociceptive thresholds at both acute and more
chronic time points. Thus, there exists at least one func-
tional example of a gene functioning in this very unique
pain model in ways similar to those observed in models of
inflammatory and neuropathic pain.
Methods
Animals
Male C57/B6J mice aged 12–14 weeks were purchased
from a commercial supplier (Jackson Labs, Sacramento,
CA) and were allowed to habituate to the animal facility
for a minimum of 10 days prior to the experiments.
Mice were housed in groups of 4 in a cage on a 12-hr
light/dark cycle and an ambient temperature of 22 ±
1°C, with food and tap water available ad libitum. Allanimal procedures were approved by the Veterans Af-
fairs Palo Alto Health Care System Institutional Animal
Care and Use Committee (Palo Alto, CA) and followed
the animal subjects guidelines of the International
Association for the Study of Pain published in PAIN, 16
(1983) 109–110.Limb fracture and cast immobilization
Mice were anesthetized with 1.5% Isoflurane in air and re-
ceived a distal tibial fracture. Immediately following frac-
ture and while still under anesthetic, a cast was placed
around the injured hindpaw so as to encase it entirely
[15]. To ensure the proper and consistent placement of
the cast, it was elongated to wrap about the abdomen of
the animal. After fracture and casting, the mice were given
subcutaneous Buprenorphine (0.05 mg/kg) and Baytril
(5 mg/kg) for the next three days, as well as normal saline
(1.5 ml once) for post-operative analgesia, prevention of
infection and dehydration. Mice were inspected daily to
ensure the cast was positioned properly through the
3-week period of cast immobilization. Mice were provided
with chow ad libitum; diet gels were also made available
on the cage floor for mice having undergone surgery. At
3 weeks after surgery, the mice were anesthetized and the
casts were removed using pliers.Timecourse
Behavioral and physiological measures were taken on
the injured and contralateral hindpaw 3, 5 and 7 weeks
after fracture; the 3-week timepoint was 24 hours after
cast removal. Tissue collected at the 3 and 7-week
timepoints was used for the molecular studies (micro-
array, qPCR, ELISA).Physiological measures
Hindpaw temperature
The temperature of the hindpaw was measured using a
fine wire thermocouple (Omega) applied to the paw
skin, as described previously [50]. The investigator held
the wire using an insulating Styrofoam block. Three sites
were tested over the dorsum of the hindpaw: the space
between the first and second metatarsals (medial), the
second and third metatarsals (central), and the fourth
and fifth metatarsals (lateral). After a site was tested in
one hindpaw the same site was immediately tested in
the contralateral hindpaw. The testing protocol was
medial dorsum right then left, central dorsum right then
left, lateral dorsum right then left, medial dorsum left
then right, central dorsum left then right, and lateral
dorsum left then right. The six measurements for each
hindpaw were averaged for the mean temperature.
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A laser sensor technique was used to determine the
dorsal–ventral thickness of the hindpaw, as we have pre-
viously described [50]. The measurement sensor device
used in these experiments (Limab) has a measurement
range of 200 mm with a 0.01 mm resolution.
Behavioral testing
Mechanical hypersensitivity
Calibrated monofilaments (Stoelting Co., Wood Dale,
IL) were applied to the plantar surface of the hindpaw
and the 50% threshold to withdraw (grams) was calcu-
lated as previously described [51].
Hindpaw unweighting
An incapacitance device (IITC Inc.) was used to measure
hindpaw unweighting. The mice were manually held in a
vertical position over the apparatus with the hindpaws
resting on separate metal scale plates and the entire
weight of the mouse was supported on the hindpaws.
The duration of each measurement was 6 s and 6 con-
secutive measurements were taken at 10s intervals. All 6
readings were averaged to calculate the bilateral hindpaw
weight-bearing values.
Microarray analysis
Microarray analysis was performed in the L4/L5 region
of the ipsilateral spinal cord at 3 and 7 weeks in CRPS
(n = 3/group; tissue from 2 animals combined for each
sample) and age-matched control mice. Microarray pro-
filing was performed using an Agilent Whole Mouse
Genome Microarray (44 k arrays) at the Stanford Func-
tional Genomics Facility. Results were imported into R
using the Bioconductor package for microarray analysis
where RMA normalization was performed and filtering of
absent/present labels performed. Statistical analysis of the
3- and 7-week timepoint compared to the control
timepoint was then performed using Students t test. False
Discovery Rate (FDR) was used to adjust p-values to take
into account multiple comparison effects and significance
was considered reached at an absolute fold change of 1.5
and a FDR-adjusted p-value of less than 0.05.
Pathway analysis
Ingenuity Software was used to perform whole pathway
analysis in the identification of affected networks and
their relationship to each other based on the differential
expression between control, 3- and 7-week CRPS mice.
Briefly, our data set containing gene identifiers and
corresponding expression values was uploaded into the
application. Each identifier was mapped to its corre-
sponding object in the Ingenuity® Knowledge Base.
Differentially expressed genes, called network eligible
molecules, were overlaid onto a global molecularnetwork developed from information contained in
the Ingenuity Knowledge Base. Networks of Network
Eligible Molecules were then algorithmically generated
based on their connectivity. The pathway presented was
chosen from following candidate gene validation. Right-
tailed Fisher’s exact test was used to calculate a p-value
determining the probability that the pathway is due to
chance alone.RNA isolation and quantitative real-time polymerase
chain reaction (PCR)
Mice were first euthanized by carbon dioxide asphyxiation
and spinal cord tissue was harvested by extrusion. Ipsilat-
eral L4/L5 lumbar spinal cord segments were dissected on
a chilled surface. Dissected tissue was then quick-frozen in
liquid nitrogen and stored at −80°C until required for ana-
lysis. Total RNA was isolated from spinal cord using the
RNeasy Mini Kit (Qiagen) according to the manufacturer's
instructions. The purity and concentration were deter-
mined spectrophotometrically. The cDNA was subse-
quently synthesized using an iScript cDNA Synthesis Kit
(Bio-Rad Laboratories). Real time PCR reactions were
conducted using the SYBR Green PCR master mix
(Applied Biosystems) and performed on the ABI 7900HT
sequencing detection system (Applied Biosystems). The
data from real time PCR experiments were analyzed by
the comparative CT method as described in the manufac-
turer’s manual.Enzyme-linked immunosorbent assay (ELISA)
Mice were first euthanized by carbon dioxide asphyxi-
ation and spinal cord tissue was harvested by extrusion.
Lumbar spinal cord segments were dissected on a chilled
surface. Dissected tissue was then quick-frozen in liquid
nitrogen and stored at −80°C until required for analysis.
Mouse lumbar spinal cords were homogenized in ice
cold 0.9% NaCl containing a cocktail of protease inhibi-
tors (Roche Applied Science) and centrifuged at 12,000G
for 10 min at 4°C. Supernatant fractions were then fro-
zen at −80°C until use. An aliquot was subjected to pro-
tein assay (Bio-Rad) to normalize mediator levels. CcL2
levels were assayed in duplicate by using mouse CcL2
ELISA kit (R&D Systems) according to the manufac-
turer’s instructions.Pharmacology
CcL2 administration
Recombinant full length CcL2 (ab9901, Abcam) was
reconstituted in sterile saline. CcL2 or saline were
administered intrathecally (10 or 100 ng in 5 μL; n =
8/group) or through intraplantar injections (100 or
500 μg in 10 μl).
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The CCR2 antagonist, RS504393 (Santa Cruz Biotech,
CA) was diluted in sterile saline containing DMSO
(<1 %). RS504393 or vehicle (saline with 1% DMSO)
were administered intrathecally (0.3 or 3 μg in 5 μL) or
through intraplantar injections (1 or 10 μg in 10 μl).
Statistical analysis
All data are expressed as mean ± SEM. Analysis of
repeated parametric measures was accomplished using a
one-way analysis of variance followed post-hoc Dunnett
or Bonferroni testing or a two-way analysis of variance
followed by Bonferroni testing. For simple comparisons
of two groups, a two-tailed Student t-test was employed.
Welch’s correction was used when the assumption of
equal variances was not met. Significance was set at
p < 0.05. (Prism 5; GraphPad Software, La Jolla, CA).
Additional files
Additional file 1: Table S1. Microarray results in ipsilateral spinal cord
3 weeks post fracture.
Additional file 2: Table S2. Microarray results in ipsilateral spinal cord
7 weeks post fracture.
Additional file 3: Table S3. Comparative analysis of functional
pathways regulated 3 and 7 weeks post fracture. Shaded cells indicate
the 3-week timepoint.
Additional file 4: Figure S1. Validation of transcript mRNA expression.
qPCR validation of upregulated (A), downregulated (B), and unchanged
(C) transcripts in the ipsilateral spinal cord 3 and 7 weeks after fracture.
The dotted line indicates control measures. * p<0.05. n=4/group. Errors
bars=S.E.M.
Additional file 5: Figure S2. Induction of mechanical allodynia
following the intrathecal and intraplantar administration of CcL2. Both
intrathecal (A) and intraplantar (B) administration of CcL2 resulted in
decreased mechanical thresholds compared to vehicle-treated mice.
*** p<0.001. n=7-8/group. Errors bars=S.E.M.
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